Literature DB >> 22114101

Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model.

Christopher M O'Connor1, David J Whellan, Daniel Wojdyla, Eric Leifer, Robert M Clare, Stephen J Ellis, Lawrence J Fine, Jerome L Fleg, Faiez Zannad, Steven J Keteyian, Dalane W Kitzman, William E Kraus, David Rendall, Ileana L Piña, Lawton S Cooper, Mona Fiuzat, Kerry L Lee.   

Abstract

BACKGROUND: We aimed to develop a multivariable statistical model for risk stratification in patients with chronic heart failure with systolic dysfunction, using patient data that are routinely collected and easily obtained at the time of initial presentation. METHODS AND
RESULTS: In a cohort of 2331 patients enrolled in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise TraiNing) study (New York Heart Association class II-IV, left ventricular ejection fraction ≤0.35, randomized to exercise training and usual care versus usual care alone, median follow-up of 2.5 years), we performed risk modeling using Cox proportional hazards models and analyzed the relationship between baseline clinical factors and the primary composite end point of death or all-cause hospitalization and the secondary end point of all-cause death alone. Prognostic relationships for continuous variables were examined using restricted cubic spline functions, and key predictors were identified using a backward variable selection process and bootstrapping methods. For ease of use in clinical practice, point-based risk scores were developed from the risk models. Exercise duration on the baseline cardiopulmonary exercise test was the most important predictor of both the primary end point and all-cause death. Additional important predictors for the primary end point risk model (in descending strength) were Kansas City Cardiomyopathy Questionnaire symptom stability score, higher serum urea nitrogen, and male sex (all P<0.0001). Important additional predictors for the mortality risk model were higher serum urea nitrogen, male sex, and lower body mass index (all P<0.0001).
CONCLUSIONS: Risk models using simple, readily obtainable clinical characteristics can provide important prognostic information in ambulatory patients with chronic heart failure with systolic dysfunction. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.

Entities:  

Mesh:

Year:  2011        PMID: 22114101      PMCID: PMC3692371          DOI: 10.1161/CIRCHEARTFAILURE.111.963462

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  34 in total

1.  Exercise treadmill score for predicting prognosis in coronary artery disease.

Authors:  D B Mark; M A Hlatky; F E Harrell; K L Lee; R M Califf; D B Pryor
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

2.  Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure.

Authors:  H M Krumholz; Y T Chen; V Vaccarino; Y Wang; M J Radford; W D Bradford; R I Horwitz
Journal:  Am J Cardiol       Date:  2000-05-01       Impact factor: 2.778

3.  Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.

Authors:  C P Green; C B Porter; D R Bresnahan; J A Spertus
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

4.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.

Authors:  Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

5.  Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial.

Authors:  Kathryn E Flynn; Ileana L Piña; David J Whellan; Li Lin; James A Blumenthal; Stephen J Ellis; Lawrence J Fine; Jonathan G Howlett; Steven J Keteyian; Dalane W Kitzman; William E Kraus; Nancy Houston Miller; Kevin A Schulman; John A Spertus; Christopher M O'Connor; Kevin P Weinfurt
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

Review 6.  Heart failure in women: epidemiology, biology and treatment.

Authors:  Rashmee U Shah; Liviu Klein; Donald M Lloyd-Jones
Journal:  Womens Health (Lond)       Date:  2009-09

7.  Trends in heart failure incidence and survival in a community-based population.

Authors:  Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

8.  Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).

Authors:  Liviu Klein; Barry M Massie; Jeffrey D Leimberger; Christopher M O'Connor; Ileana L Piña; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

9.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.

Authors:  Douglas S Lee; Peter C Austin; Jean L Rouleau; Peter P Liu; David Naimark; Jack V Tu
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

10.  Importance of treadmill exercise time as an initial prognostic screening tool in patients with systolic left ventricular dysfunction.

Authors:  Eileen Hsich; Eiran Z Gorodeski; Randall C Starling; Eugene H Blackstone; Hemant Ishwaran; Michael S Lauer
Journal:  Circulation       Date:  2009-06-15       Impact factor: 29.690

View more
  64 in total

1.  Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.

Authors:  Jacob P Kelly; Allison Dunning; Phillip J Schulte; Mona Fiuzat; Eric S Leifer; Jerome L Fleg; Lawton S Cooper; Steven J Keteyian; Dalane W Kitzman; Ileana L Pina; William E Kraus; David J Whellan; Christopher M O'Connor; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2016-07-06       Impact factor: 12.035

2.  Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example.

Authors:  Siyun Yang; Monique Anderson Starks; Adrian F Hernandez; Elizabeth L Turner; Robert M Califf; Christopher M O'Connor; Robert J Mentz; Kingshuk Roy Choudhury
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

3.  Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

Authors:  Tariq Ahmad; Mona Fiuzat; Benjamin Neely; Megan L Neely; Michael J Pencina; William E Kraus; Faiez Zannad; David J Whellan; Mark P Donahue; Ileana L Piña; Kirkwood F Adams; Dalane W Kitzman; Christopher M O'Connor; G Michael Felker
Journal:  JACC Heart Fail       Date:  2014-06       Impact factor: 12.035

Review 4.  The practical role of echocardiography in selection, implantation, and management of patients requiring LVAD therapy.

Authors:  Maria Chiara Todaro; Bijoy K Khandheria; Timothy E Paterick; Matt M Umland; Vinay Thohan
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

5.  Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Authors:  Andrew P Ambrosy; Ankeet S Bhatt; Amanda L Stebbins; Lisa M Wruck; Marat Fudim; Stephen J Greene; William E Kraus; Christopher M O'Connor; Ileana L Piña; David J Whellan; Robert J Mentz
Journal:  Am Heart J       Date:  2018-02-11       Impact factor: 4.749

6.  Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.

Authors:  Adil Yunis; Gheorge Doros; Ivan Luptak; Lawreen H Connors; Flora Sam
Journal:  Am J Cardiol       Date:  2019-04-09       Impact factor: 2.778

7.  The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure.

Authors:  Tariq Ahmad; Mona Fiuzat; Daniel B Mark; Ben Neely; Megan Neely; William E Kraus; Dalane W Kitzman; David J Whellan; Mark Donahue; Faiez Zannad; Ileana L Piña; Kirkwood Adams; Christopher M O'Connor; G Michael Felker
Journal:  Am Heart J       Date:  2013-11-04       Impact factor: 4.749

8.  Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION).

Authors:  Kishan S Parikh; Adrian Coles; Phillip J Schulte; William E Kraus; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Mona Fiuzat; David J Whellan; Christopher M O'Connor; Robert J Mentz
Journal:  Am J Cardiol       Date:  2016-07-29       Impact factor: 2.778

9.  Relation between volume of exercise and clinical outcomes in patients with heart failure.

Authors:  Steven J Keteyian; Eric S Leifer; Nancy Houston-Miller; William E Kraus; Clinton A Brawner; Christopher M O'Connor; David J Whellan; Lawton S Cooper; Jerome L Fleg; Dalane W Kitzman; Alain Cohen-Solal; James A Blumenthal; David S Rendall; Ileana L Piña
Journal:  J Am Coll Cardiol       Date:  2012-10-10       Impact factor: 24.094

10.  Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).

Authors:  Lauren B Cooper; Robert J Mentz; Jie-Lena Sun; Phillip J Schulte; Jerome L Fleg; Lawton S Cooper; Ileana L Piña; Eric S Leifer; William E Kraus; David J Whellan; Steven J Keteyian; Christopher M O'Connor
Journal:  Circ Heart Fail       Date:  2015-11       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.